Dynavax Technologies Corporation (NASDAQ:DVAX) Receives Consensus Rating of “Hold” from Analysts

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) have been given a consensus rating of “Hold” by the five research firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $24.3333.

DVAX has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 27th. Finally, William Blair lowered shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research note on Wednesday, December 24th.

Dynavax Technologies Stock Performance

Shares of Dynavax Technologies stock opened at $15.41 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94. The firm has a 50 day simple moving average of $12.12 and a 200 day simple moving average of $10.95. Dynavax Technologies has a fifty-two week low of $9.20 and a fifty-two week high of $15.49. The firm has a market cap of $1.81 billion, a P/E ratio of -41.65 and a beta of 0.89.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.07. The firm had revenue of $94.88 million for the quarter, compared to analyst estimates of $94.00 million. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%. Sell-side analysts predict that Dynavax Technologies will post 0.32 earnings per share for the current fiscal year.

Insider Transactions at Dynavax Technologies

In other Dynavax Technologies news, COO David F. Novack sold 30,000 shares of Dynavax Technologies stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $15.49, for a total transaction of $464,700.00. Following the completion of the sale, the chief operating officer owned 111,451 shares of the company’s stock, valued at approximately $1,726,375.99. The trade was a 21.21% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.98% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in DVAX. Hantz Financial Services Inc. increased its holdings in Dynavax Technologies by 236.9% in the third quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 2,710 shares during the last quarter. LSV Asset Management acquired a new position in shares of Dynavax Technologies during the 3rd quarter worth about $89,000. Osaic Holdings Inc. increased its stake in shares of Dynavax Technologies by 15.1% in the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 1,226 shares during the last quarter. Callan Family Office LLC bought a new stake in shares of Dynavax Technologies in the 2nd quarter valued at about $107,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Dynavax Technologies in the 3rd quarter valued at approximately $109,000. 96.96% of the stock is currently owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.